Applied DNA Corp (APDN) Long-Term Debt to Capital Ratio
Stable management under James Hayward is successfully implementing industrial-scale RNA component synthesis methods at Applied DNA Sciences (APDN). This price chart reflects the metric at 0.00. The business creates linear DNA for medicine and logistics control, which minimizes risks by operating across different sectors. Revenue is generated through the supply of PCR materials for pharmacology and molecular markers that protect textiles and pharmaceuticals from counterfeiting.
Analytical breakdowns for Applied DNA Sciences
The market views Applied DNA Sciences (APDN) as a promising high-tech asset with scaling potential. The metric compares liabilities with maturities exceeding one year to equity to determine the degree of financial leverage. By analyzing the current long-term debt-to-equity ratio, an investor assesses default risk and the stability of the financing structure. A balanced debt load that does not hinder expansion amid growing demand is critical for the synthesis of DNA tags. This instrument is categorized as a venture security.